Jonathan G Drachman
Overview
Explore the profile of Jonathan G Drachman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fayad L, Ansell S, Advani R, Coiffier B, Stuart R, Bartlett N, et al.
Leuk Lymphoma
. 2015 Feb;
56(9):2569-78.
PMID: 25651427
Single-agent dacetuzumab has demonstrated antitumor activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Preclinical data demonstrated improved dacetuzumab antitumor activity in combination with rituximab, ± chemotherapy. We designed a phase...
2.
de Vos S, Forero-Torres A, Ansell S, Kahl B, Cheson B, Bartlett N, et al.
J Hematol Oncol
. 2014 Jun;
7:44.
PMID: 24919462
Background: Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy have a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including DLBCL and is...
3.
Drachman J, Senter P
Hematology Am Soc Hematol Educ Program
. 2013 Dec;
2013:306-10.
PMID: 24319196
For more than a century, the concept of a "magic bullet" to deliver cytotoxic therapy to the site of disease has been envisioned but only recently have technological advances enabled...
4.
Kung Sutherland M, Walter R, Jeffrey S, Burke P, Yu C, Kostner H, et al.
Blood
. 2013 Jun;
122(8):1455-63.
PMID: 23770776
Outcomes in acute myeloid leukemia (AML) remain unsatisfactory, and novel treatments are urgently needed. One strategy explores antibodies and their drug conjugates, particularly those targeting CD33. Emerging data with gemtuzumab...
5.
Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt D, et al.
Leuk Lymphoma
. 2012 Jul;
54(2):277-83.
PMID: 22775314
Dacetuzumab, a CD40-targeted, humanized antibody, mediates antitumor activity through effector cell functions and direct apoptotic signal transduction. Preclinical studies demonstrated synergistic activity between dacetuzumab, gemcitabine and rituximab against non-Hodgkin lymphoma...
6.
Hussein M, Berenson J, Niesvizky R, Munshi N, Matous J, Sobecks R, et al.
Haematologica
. 2010 Feb;
95(5):845-8.
PMID: 20133895
This first-in-human, phase I study evaluated the safety, maximum-tolerated dose, pharmacokinetics, and antitumor activity of dacetuzumab in 44 patients with advanced multiple myeloma. Patients received intravenous dacetuzumab, either in 4...
7.
Furman R, Forero-Torres A, Shustov A, Drachman J
Leuk Lymphoma
. 2009 Dec;
51(2):228-35.
PMID: 20038235
Despite advances in therapy, chronic lymphocytic leukemia remains an incurable disease and novel, effective therapies are needed. In this open-label, dose-escalation, phase I study, dacetuzumab (IgG1 humanized monoclonal antibody) was...
8.
Advani R, Forero-Torres A, Furman R, Rosenblatt J, Younes A, Ren H, et al.
J Clin Oncol
. 2009 Jul;
27(26):4371-7.
PMID: 19636010
Purpose: To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL). Patients And Methods: In this open-label,...
9.
Raza A, Jurcic J, Roboz G, Maris M, Stephenson J, Wood B, et al.
Leuk Lymphoma
. 2009 Jun;
50(8):1336-44.
PMID: 19557623
A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies. In this study, higher doses than previously tested and...
10.
Johnson H, Gandhi M, Shafizadeh E, Langer N, Pierce E, Paw B, et al.
Exp Hematol
. 2009 May;
37(8):901-8.
PMID: 19460416
Objective: A missense mutation in the microtubule-associated serine/threonine-like kinase gene (MASTL, FLJ14813) on human chromosome 10 was previously linked to a novel form of autosomal dominant inherited thrombocytopenia in a...